Press releases

Regulatory press release 2021-10-15

Xspray Pharma’s Nomination Committee for the Annual General Meeting 2022

Regulatory press release 2021-10-13

Xspray Pharma has obtained results from bioequivalence studies with HyNap-Dasa ANDA and decides to focus on its improved dasatinib product, Dasynoc™

Press release 2021-08-30

All participants in Xspray Pharma studies have received their dose of generic version of dasatinib, HyNap-Dasa ANDA

Press release 2021-08-06

Xspray Pharma has initiated studies with generic version of dasatinib, HyNap-Dasa ANDA

Regulatory press release 2021-08-06

Xspray Pharma publishes interim report Q2 , January – June 2021

All press releases

Latest report
Annual Report 2018
Subscribe
Get our latest press releases and reports
Subscribe
Submit to our press releases and get an email every time we publish a press release or report on our website.
Type*
Reports
Press releases
E-mail*

Välj språk*
Swedish
English
When clicked on Send I agree that my personal information will be saved. Read more
Name
This field is for validation purposes and should be left unchanged.

Press contact

Per Andersson, CEO

+46 (0)8 730 37 00

per.andersson@xspray.com

Presentations and interviews

Interview with Per Andersson at Redeye, October 14, 2021

Interview with Per Andersson at Redeye, August 12, 2021

Presentation at Redeye Growth Day, June 2, 2021

Media